Research:                          

ADD / ADHD

ADHD Efficacy Summary

The following is from Vincent Monastra’s book (2008), Unlocking the Potential of Patients with ADHD. He is a respected researcher in this field and has published an earlier review of the research literature which was cited on-line in the CHADD “What We Know” series. That review is outdated and the following update is a more current reflection on the scientific research into the utility of neurofeedback for attention issues.

Additional Family Costs in ADD

The annual average expenditure (direct cost) per ADHD patient was $1,574, compared to $541 among matched controls. The annual average payment (direct plus indirect cost) per family member was $2,728 for non-ADHD family members of ADHD patients versus $1,440 for family members of matched controls. Both patient and family cost differences were significant at the 95% confidence level.

Medication Costs for ADD

The goal of this study was to estimate the total expected costs for the treatment and management of school age children with ADHD using 6 commonly prescribed pharmacotherapies: methylphenidate immediate release/extended-release (MPH IR/ER), methylphenidate immediate-release (MPH IR), Metadate CD (branded MPH IR/ER), Concerta (branded MPH ER), Ritalin (branded MPH IR), and Adderall (a combination of dextroamphetamine and amphetamine salts). 

Efficacy of Neurofeedback for ADHD

EEG Biofeedback, or Neurofeedback (NFB) training has sufficient research behind it that it is now considered by various institutional bodies and scientific publications to be as effective as any other treatment and superior to most for ADD/ADHD. This support is listed below:...